Phase II Study to Determine the Efficacy of Bendamustin (Ribomustin) in Patients With Recurrent Small Cell Bronchial Carcinoma After Cytostatic Polychemotherapy
Phase II Study to determine the efficacy of Bendamustin(Ribomustin) in patients with
recurrent small cell bronchial carcinoma after cytostatic polychemotherapy
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determination of response rate ( CR + PR) after cytostatic therapy with Bendamustin 120mg/m2, day 1+2, repeat d 22
Ulrich Keilholz, MD
Principal Investigator
Charité Campus Benjamin Franklin University Clinic
Germany: Federal Institute for Drugs and Medical Devices
Haema CBF SCLC UK/AS 02
NCT00168922
February 2001
December 2006
Name | Location |
---|